Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems

Journal of Biomedical Science

Volumn 21, Issue 1, 2014, Pages

  Tahamtan, Alireza ^a,b   Ghaemi, Amir ^a,c   Gorji, Ali ^c,d   Kalhor, Hamid R ^e   Sajadian, Azadeh ^c   Tabarraei, Alijan ^a   Moradi, Abdolvahab ^a   Atyabi, Fatemeh ^f   Kelishadi, Mishar ^a  

^a GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Shefa Neuroscience Research Centre   (Iran)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e SHARIF UNIVERSITY OF TECHNOLOGY   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chitosan; DNA vaccine; E7; Human papilloma virus; Tumor

Indexed keywords

CHITOSAN; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; NANOCARRIER; PROTEIN E7; RECOMBINANT VACCINE; WART VIRUS VACCINE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SIZE; CD8+ T LYMPHOCYTE; CELL COUNT; CHO CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; GENETIC TRANSFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PARTICLE SIZE; UTERINE CERVIX CANCER; ZETA POTENTIAL; ANIMAL; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIROLOGY;

ANIMALS; CELL LINE, TUMOR; CHITOSAN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES, DNA;

EID: 84906536057     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-014-0069-z     Document Type: Article

References (31)

1. Emerging human papillomavirus vaccines. B Ma, B Maraj, NP Tran, J Knoff, A Chen, RD Alvarez, CF Hung, TC Wu, Expert Opin Emerg Drugs 2012 17 4 469 492 10.1517/14728214.2012.744393 23163511
2. Genital human papillomavirus infections: current and prospective therapies. MA Stanley, J Gen Virol 2012 93 Pt 4 681 691 10.1099/vir.0.039677-0 22323530
3. Therapeutic HPV DNA vaccines. K Lin, E Roosinovich, B Ma, CF Hung, TC Wu, Immunol Res 2010 47 1-3 86 112 10.1007/s12026-009-8141-6 20066511
4. Human papillomavirus proteins as prospective therapeutic targets. CL Pang, F Thierry, Microb Pathog 2013 58 55 65 10.1016/j.micpath.2012.11.002 23164805
5. Immunotherapy for cervical cancer: research status and clinical potential. JH Su, A Wu, E Scotney, B Ma, A Monie, CF Hung, TC Wu, BioDrugs 2010 24 2 109 129 10.2165/11532810-000000000-00000 20199126
6. Recombinant lambda-phage nanobioparticles for tumor therapy in mice models. A Ghaemi, H Soleimanjahi, P Gill, Z Hassan, SR Jahromi, F Roohvand, Genet Vaccines Ther 2010 8 3 10.1186/1479-0556-8-3 20459865
7. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. MP Morrow, J Yan, NY Sardesai, Expert Rev Vaccines 2013 12 3 271 283 10.1586/erv.13.23 23496667
8. Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. M Naderi, A Saeedi, A Moradi, M Kleshadi, MR Zolfaghari, A Gorji, A Ghaemi, Virol Sin 2013 28 3 167 173 10.1007/s12250-013-3291-z 23709057
9. Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. A Sajadian, A Tabarraei, H Soleimanjahi, F Fotouhi, A Gorji, A Ghaemi, Arch Virol 2014 doi:10.1007/s00705-014-2024-4
10. The future of human DNA vaccines. L Li, F Saade, N Petrovsky, J Biotechnol 2012 162 2-3 171 182 10.1016/j.jbiotec.2012.08.012 22981627
11. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. A Ghaemi, H Soleimanjahi, T Bamdad, S Soudi, E Arefeian, SM Hashemi, M Ebtekar, Comp Immunol Microbiol Infect Dis 2007 30 4 197 210 17335902
12. Protection of mice by a lambda-based therapeutic vaccine against cancer associated with human papillomavirus type 16. A Ghaemi, H Soleimanjahi, P Gill, ZM Hassan, S Razeghi, M Fazeli, SM Razavinikoo, Intervirology 2011 54 3 105 112 10.1159/000320197 20956855
13. Strategies for DNA vaccine delivery. HO Alpar, I Papanicolaou, VW Bramwell, Expert Opin Drug Deliv 2005 2 5 829 842 10.1517/17425247.2.5.829 16296781
14. Applications of, and future challenges for, genetic vaccines. SA Johnston, BX Qu, M McGuire, K Stemke-Hale, K Sykes, Dev Biol (Basel) 2000 104 3 8
15. DNA vaccines-challenges in delivery. CJ Pachuk, DE McCallus, DB Weiner, C Satishchandran, Curr Opin Mol Ther 2000 2 2 188 198 11249641
16. Chitosan as a novel nasal delivery system for vaccines. L Illum, I Jabbal-Gill, M Hinchcliffe, AN Fisher, SS Davis, Adv Drug Deliv Rev 2001 51 1-3 81 96 10.1016/S0169-409X(01)00171-5 11516781
17. Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. A Bolhassani, S Javanzad, T Saleh, M Hashemi, MR Aghasadeghi, SM Sadat, Hum Vaccin Immunother 2013 10 2 2013
18. Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery. A Masotti, G Ortaggi, Mini Rev Med Chem 2009 9 4 463 469 10.2174/138955709787847976 19356124
19. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection. G Feng, Q Jiang, M Xia, Y Lu, W Qiu, D Zhao, L Lu, G Peng, Y Wang, PLoS One 2013 8 4 61135 10.1371/journal.pone.0061135 23637790
20. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. DA Zaharoff, CJ Rogers, KW Hance, J Schlom, JW Greiner, Vaccine 2007 25 11 2085 2094 10.1016/j.vaccine.2006.11.034 17258843
21. Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines. SP Akhlaghi, S Saremi, SN Ostad, R Dinarvand, F Atyabi, Nanomedicine 2010 6 5 689 697 20172052
22. Thiolated chitosan nanoparticles as an oral delivery system for Amikacin: in vitro and ex vivo evaluations. F Atyabi, F Talaie, R Dinarvand, J Nanosci Nanotechnol 2009 9 8 4593 4603 10.1166/jnn.2009.1090 19928123
23. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. P Yousefpour, F Atyabi, E Vasheghani-Farahani, AA Movahedi, R Dinarvand, Int J Nanomed 2011 6 1977 1990
24. Chitosan nanoparticles as a potential nonviral gene delivery for HPV-16 E7 into mammalian cells. A Tahamtan, A Tabarraei, A Moradi, M Dinarvand, M Kelishadi, A Ghaemi, F Atyabi, Artif Cells Nanomed Biotechnol 2014 doi:10.3109/21691401.2014.893522
25. Generation of toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. M Bivas-Benita, M Laloup, S Versteyhe, J Dewit, J De Braekeleer, E Jongert, G Borchard, Int J Pharm 2003 266 1-2 17 27 14559390
26. Induction of Th1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. GP Li, ZG Liu, B Liao, NS Zhong, Cell Mol Immunol 2009 6 1 45 50 10.1038/cmi.2009.6 19254479
27. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. K Khatri, AK Goyal, PN Gupta, N Mishra, SP Vyas, Int J Pharm 2008 354 1-2 235 241 18182259
28. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice. L Jiang, F Qian, X He, F Wang, D Ren, Y He, K Li, S Sun, C Yin, J Gene Med 2007 9 4 253 264 10.1002/jgm.1017 17397104
29. Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. K Zhao, X Shi, Y Zhao, H Wei, Q Sun, T Huang, X Zhang, Y Wang, Vaccine 2011 29 47 8549 8556 10.1016/j.vaccine.2011.09.029 21945253
30. The effect of conjugation to gold nanoparticles on the ability of low molecular weight chitosan to transfer DNA vaccine. X Zhou, X Zhang, X Yu, X Zha, Q Fu, B Liu, X Wang, Y Chen, Y Chen, Y Shan, Y Jin, Y Wu, J Liu, W Kong, J Shen, Biomaterials 2008 29 1 111 117 10.1016/j.biomaterials.2007.09.007 17905427
31. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. B Klencke, M Matijevic, RG Urban, JL Lathey, ML Hedley, M Berry, J Thatcher, V Weinberg, J Wilson, T Darragh, N Jay, M Da Costa, JM Palefsky, Clin Cancer Res 2002 8 5 1028 1037 12006515